{"name":"Atreca, Inc.","slug":"atreca-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":66829000,"netIncome":-97157000,"cash":30819000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQaktuZXdhYm5TRERzZl9WTjBuSjNWM0NvLWFyazI0WUoybUF3Wlg2YnJqSUJqMmlFdjNMemhPWWZkbWVYMi1lVW1rR1N0WTdkTGMtTGZBMkFRLVVBX0RuNnctRnI3ODdMUFZOTk5pQW5YV01SRXpBT0lHeUctcVMwWE1TMTZpTzBSc3ZxUHBkdHFWaFlZMzl5N01GNU5za0h2a0xqeDFZWHBnSGZDenFKTUVfZFpqLTNjVjBCSHpmbURtQTJXcFhkQTZQa1BHTVFINVlBSVhQZ1FnZ3F4a3FhV09URUdldDBvYlN4bXJR?oc=5","date":"2026-02-23","type":"pipeline","source":"BioSpace","summary":"Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors - BioSpace","headline":"Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOYW9UYU1aSzNuMWZFVXl4MGNzajBiUVdGeUtxa3pWWDZvYUs5X0U4ZXdlR1dnNGJqV0FzYUUxRklKSkZ6Q3VhZ2MtcDBUeFk5N21YbzJIemlWVF9FWlpJYm9JeWU1b0VLNktuek5wbG1qVWRUcU5sWFN3a3d2TGlEZGNvZkFmdG1vdmhpdWxoWGNYRWFxa1JWS1Iwd1JvVFh0M0w4a1Y4M1BTY3Qtb3ozUUNURERsclU?oc=5","date":"2025-11-25","type":"pipeline","source":"Pharmaceutical Technology","summary":"Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m - Pharmaceutical Technology","headline":"Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPTzZsVFg5QTI5akdvWjdqXzM3UlVfY0JVVDByQkZ6dnNkTkFZeUw5YkNQUjkzNnRCZFJEYWh0WjNHRnpjdmZqWlFWWlIyYzV6Q1lkYnd4SWgyTnFzUHBYb2RsZ3ZvUVpwb2o1aFBNakFsb2kxVDJXMXA1RnFFcGVHaTMtZDhnYV95RTgtQVhkV3RReDNlQXFuOHZfbGJqdw?oc=5","date":"2024-06-27","type":"pipeline","source":"PharmaLive","summary":"Biopharma layoff tracker 2023: Atreca, Galera, INOVIO and more cut staff - PharmaLive","headline":"Biopharma layoff tracker 2023: Atreca, Galera, INOVIO and more cut staff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPZnpIc09lalQ4U1dHMVlJYXNyNm9HelhyTEU4akFnMjcwY25wWW1EdXZmRVZScmhFaHR2b2toNjd0SURRUk9pWEZTMDJxbk5vNHZic2dHT0NqUTBteWJTOVVZbTc0MUFtUFZHdnBuMXFUc21kS3pueTNaRFl5ZUJKMXBBeVpXQUk?oc=5","date":"2023-12-31","type":"pipeline","source":"BioSpace","summary":"Waves of Employee Cuts Hit Biopharma in 2023 - BioSpace","headline":"Waves of Employee Cuts Hit Biopharma in 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOTVhIOW5HcFpQSGc0SjlGWlRxOW5jUkdpQWRneFJfQUpTcHlyTG5LeGNhODBHVDFudXpfVURPYmdXWUFjNjljcmNnWkM5QmdvNkxBM1ZEYWdUWFdaRjItNV83eWNZdEpxR25ST3R0UmFlMmxCZzFkcDl3MFlieVB6anVmeG12emoxZG85N2xGVUlfU3IxNGprZWRlNnprUmhmeDBnRFlOaHVBUVR0TWttdS13?oc=5","date":"2023-12-26","type":"deal","source":"Streetwise Reports","summary":"Biotech Bolsters ADC Pipeline Through Atreca Asset Buy - Streetwise Reports","headline":"Biotech Bolsters ADC Pipeline Through Atreca Asset Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQemZzdUx6QXduTlNHUGRpeU8xSWtQVm56SV9fQU80NFV1NHhaWi1JQzVpMDFfVTZ6ZHRRZTJEeWQzMHZzMXJ4Q3I1U0Y4Ymx3N2Q2d0dlT0NwMmNsamJ3d3Zmc0VUQXdmVFdLcXBxRkpYenV2THhvRHZhbld5cFpHd1JjbUxMeWx3eDVqSDRBRUFNN043U1JrV3E5M3pwd0FYd3Vqank0MndDSWxZdjJUeQ?oc=5","date":"2023-11-15","type":"trial","source":"Clinical Trials Arena","summary":"Atreca downsizes again to focus on antibody-drug conjugate programmes - Clinical Trials Arena","headline":"Atreca downsizes again to focus on antibody-drug conjugate programmes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNWGlBSEtFRDVOdlJnbDFiOUx5T0NJLTR6NmFudTF3dTlBN09FNzEydU9oRjkwT3RfZ2NyUGpBMndRbmdKbFBFaFRuXzhUeHFlM3FadmtiaVRqNEJ2WkJUQTc5MDZxaW10NlNEcy14ZzZDNDRDbVRpTWVMQi1fbzRqMF9QbHphakZjZEdGMU9HSnc4Rm9MbGhfT0xOMzdJVHpXLTZVSFhDMWtOSnUtN1I5VkR3?oc=5","date":"2023-11-15","type":"earnings","source":"Fierce Biotech","summary":"Atreca, facing Q1 funding cliff edge, cuts head count by 40% for 2nd time in 3 months - Fierce Biotech","headline":"Atreca, facing Q1 funding cliff edge, cuts head count by 40% for 2nd time in 3 months","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNaXlzVEF5TzFjeGtiWEptT0lpWExxODRqYkZ6bU42bTRQOFg4S1Z6RE93WkRGUXoxMUF5VlZqS1RJeWR5eFQ0Nm1HSGp4SmlHdVkzMFlfMjV6aFJCZHd1SmdUd3VUUnNiQ2xYajA0YnVFS1M5Z3pZUFVCaWxJc2NrelBMZWRWV2R4cHhUcm1iYzBYM2hOYjVReWx5MDVQTXF1RGlhaFJ5WTFvcy1JTTRKSFdVbDlIdm1IeElJTUxaWGVGazB1WExxV09LRHlxSzNMSEZIX1JOcmh6N2JzSENneDNxUXBhVWllWFlxYWJ6OW5lTmxrdXN5czFySGItR0NOelJURFpncXhNNjc4UllPRzE0Ymw?oc=5","date":"2020-07-08","type":"deal","source":"Business Wire","summary":"Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies - Business Wire","headline":"Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQMG9paGd6S0JjZEZSTy1LaGFJLXVUc3ZEOU9NeTZpbnpHYWpiemxRNy1BdXBDazJmMWtrazczNzF2NXJJWTFrZWJaS1lOam5YQzhvdFNhR2lkUTdPaVhRQ00xQ0tLQzNiNlZwQjROS2d2SEZQTFBKbklxTXZncHVESUNoZWc5bEJRV09QUlZZRkpkNURHMEJNWmdaNmNubXo5amhNbkFESmF3eHQtWkhtSll3?oc=5","date":"2019-05-26","type":"pipeline","source":"The Business Journals","summary":"3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400 million - The Business Journals","headline":"3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400 million","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":66829000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-97157000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":30819000,"cashHistory":[],"totalAssets":155030000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}